 "Lonza in talks with KKR to buy Capsugel")
Lonza, the Swiss manufacturer of pharmaceutical and specialty ingredients, has said that it is in final negotiations with KKR regarding the potential acquisition of the US-based Capsugel, the manufacturer of two-piece hard gelatin capsules (the preferred solid oral dosage form). If the deal materialises, then experts believe that it would be worth more than $ 5 billion.
“Lonza confirms that it has expressed a strong interest in this successful company as it would fit perfectly with Lonza’s Healthcare Continuum strategy and strengthen its position as leading supplier to a number of important healthcare markets. A successful acquisition would be value adding and be within Lonza’s stated acquisition criteria,” said Lonza in a statement.
Capsugel designs, develops and manufactures a wide range of innovative dosage forms for the biopharmaceutical and consumer health and nutrition industries. Its diversified customer base includes companies that make branded, generic and specialty pharmaceuticals; biotech products; over-the-counter medicines; vitamins and dietary supplements.